Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Neurogene (NGNE) EBITDA Margin: 2019-2025

Historic EBITDA Margin for Neurogene (NGNE) over the last 3 years, with Sep 2025 value amounting to 56,661.90%.

  • Neurogene's EBITDA Margin fell 6007494.00% to 56,661.90% in Q3 2025 from the same period last year, while for Sep 2025 it was 15,952.46%, marking a year-over-year increase of 947714.00%. This contributed to the annual value of -8,930.27% for FY2024, which is 20744098.00% down from last year.
  • Per Neurogene's latest filing, its EBITDA Margin stood at 56,661.90% for Q3 2025, which was up 60.77% from 35,244.59% recorded in Q2 2025.
  • In the past 5 years, Neurogene's EBITDA Margin registered a high of 434,500.00% during Q1 2023, and its lowest value of 3,119.44% during Q1 2024.
  • Its 3-year average for EBITDA Margin is 133,606.80%, with a median of 56,661.90% in 2025.
  • In the last 5 years, Neurogene's EBITDA Margin plummeted by 43,138,056bps in 2024 and then soared by 3,146,711bps in 2025.
  • Neurogene's EBITDA Margin (Quarterly) stood at 86,664.71% in 2023, then crashed by 8,146,857bps to 5,196.14% in 2024, then plummeted by 6,007,494bps to 56,661.90% in 2025.
  • Its EBITDA Margin was 56,661.90% in Q3 2025, compared to 35,244.59% in Q2 2025 and 32,398.75% in Q1 2025.